论文部分内容阅读
目的探究布地奈德联合沙丁胺醇对支气管哮喘急性发作患者血清肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)、高迁移率族蛋白1(HMGB1)水平及肺功能的影响。方法选取林州市人民医院2014年4月—2016年8月收治的89例支气管哮喘患者,随机分为对照组44例和观察组45例。对照组行雾化吸入2.5 ml氯化钠+1 ml沙丁胺醇治疗;观察组于对照组基础上雾化吸入2 ml布地奈德治疗;两组均治疗7 d。观察比较两组治疗前后血清TNF-α、CRP、HMGB1水平及1 s用力呼气容积(FEV1)、呼气峰值流速(PEF)昼夜变异率及肺活量(VC)水平。结果与对照组比较,治疗后观察组血清CRP、TNF-α、HMGB1水平均较低,差异有统计学意义(P<0.05);治疗后观察组PEF昼夜变异率(11.39±2.35)%低于对照组(22.01±3.03)%,VC及FEV1水平均高于对照组,差异有统计学意义(P<0.05)。结论布地奈德与沙丁胺醇联合治疗支气管哮喘急性发作,可有效改善患者肺功能及血清TNF-α、CRP、HMGB1水平。
Objective To investigate the effects of budesonide combined with salbutamol on serum levels of tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), high mobility group box 1 (HMGB1) and lung function in patients with acute asthma attack. Methods 89 patients with bronchial asthma admitted from April 2014 to August 2016 in Linzhou People’s Hospital were randomly divided into control group (n = 44) and observation group (n = 45). The control group were treated with nebulization of 2.5 ml sodium chloride and 1 ml salbutamol. The observation group was treated with inhalation of 2 ml budesonide on the basis of the control group. Both groups were treated for 7 days. The levels of TNF-α, CRP, HMGB1, forced expiratory volume at 1 second (FEV1), diurnal variability of peak expiratory flow (PEF) and vital capacity (VC) were compared between the two groups before and after treatment. Results Compared with the control group, the serum levels of CRP, TNF-α and HMGB1 in the observation group after treatment were lower (P <0.05), and the diurnal variation rate of PEF in the observation group after treatment was 11.39 ± 2.35% The control group (22.01 ± 3.03)%, VC and FEV1 levels were higher than the control group, the difference was statistically significant (P <0.05). Conclusion Budesonide combined with salbutamol in the treatment of acute exacerbation of bronchial asthma can effectively improve the lung function and serum levels of TNF-α, CRP and HMGB1.